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In the past, biofilm-related research has focused mainly on axenic biofilms. However, in nature, biofilms are often composed of
multiple species, and the resulting polymicrobial interactions influence industrially and clinically relevant outcomes such as
performance and drug resistance. In this study, we show that Escherichia coli does not affect Candida albicans tolerance to am-
photericin or caspofungin in an E. coli/C. albicans biofilm. In contrast, ofloxacin tolerance of E. coli is significantly increased in
a polymicrobial E. coli/C. albicans biofilm compared to its tolerance in an axenic E. coli biofilm. The increased ofloxacin toler-
ance of E. coli is mainly biofilm specific, as ofloxacin tolerance of E. coli is less pronounced in polymicrobial E. coli/C. albicans
planktonic cultures. Moreover, we found that ofloxacin tolerance of E. coli decreased significantly when E. coli/C. albicans bio-
films were treated with matrix-degrading enzymes such as the -1,3-glucan-degrading enzyme lyticase. In line with a role for
-1,3-glucan in mediating ofloxacin tolerance of E. coli in a biofilm, we found that ofloxacin tolerance of E. coli increased even
more in E. coli/C. albicans biofilms consisting of a high--1,3-glucan-producing C. albicans mutant. In addition, exogenous
addition of laminarin, a polysaccharide composed mainly of poly--1,3-glucan, to an E. coli biofilm also resulted in increased
ofloxacin tolerance. All these data indicate that -1,3-glucan from C. albicans increases ofloxacin tolerance of E. coli in an E.
coli/C. albicans biofilm.
Biofilms are well-structured populations of microbial cells thatare attached to a surface and embedded in a self-produced
extracellular polymer matrix (1, 2). Such biofilms can be found in
natural, industrial, and medical environments and can be em-
ployed for a variety of biotechnological applications (3–5). How-
ever, these structured communities also have great significance for
public health, as biofilm microbial cells exhibit increased toler-
ance to antimicrobial agents (6). Biofilms consisting of a single
pathogenic microorganism have been extensively studied in the
past, and multiple processes and various structural elements have
previously been implicated in axenic biofilm formation, i.e., bio-
films consisting of one microbial species. For the Gram-negative
bacterium Escherichia coli, examples include motility, virulence,
surface appendages, polysaccharides, toxin-antitoxin modules,
quorum sensing, and several stress responses (7, 8). In the fungal
opportunistic pathogen Candida albicans, morphological transi-
tion, quorum sensing, adhesins, and several transcription regula-
tors are implicated in axenic biofilm development (9–12). How-
ever, as it is becoming increasingly clear that polymicrobial
biofilms are the dominant form in nature, the scientific focus is
shifting toward polymicrobial biofilms. Communication, cell wall
components, metabolic commensalism, and competition for nu-
trients and physical resources are emerging as important factors
influencing the physiology of both multibacterial and bacterial-
fungal biofilms (13–15). For example, interaction between C. al-
bicans hyphae and Pseudomonas aeruginosa is mediated by can-
didal cell wall glucans and by factors secreted byP. aeruginosa such
as quorum-sensing molecules and phenazines (16–19). Interest-
ingly, studies have shown that compared to axenic biofilms, mi-
crobial cells in polymicrobial biofilms often show increased drug
tolerance (20–24) and virulence (25–27).
In this study, we investigated the interplay between bacteria
and fungi in a polymicrobial biofilm configuration using biofilms
composed of E. coli and C. albicans, here referred to as E. coli/C.
albicans biofilms. E. coli andC. albicans have been found to coexist
in biofilms isolated from endotracheal tubes (28; Ilse Vandecan-
delaere and Tom Coenye, Ghent University, Belgium, personal
communication). E. coli and C. albicans are also predominant
pathogens that can grow as biofilms on urinary catheters (29). In
addition, several papers describe amutually synergistic effect in in
vivo experiments (30–32). In this study, we first optimized a pro-
tocol to obtain E. coli/C. albicans biofilms. Next, we investigated
the tolerance of these species in such an E. coli/C. albicans biofilm
setup to commonly used antifungal agents with antibiofilm activ-
ity, amphotericin B and caspofungin (33), as well as to ofloxacin, a
fluoroquinolone antibiotic, and kanamycin, an aminoglycoside
antibiotic. We observed altered tolerance only to ofloxacin by E.
coli in an E. coli/C. albicans biofilm compared to an axenic E. coli
biofilm, here referred to as E. coli biofilm. Next, we sought to
understand the molecular mechanism underlying the increased
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ofloxacin tolerance of E. coli in E. coli/C. albicans biofilms. Our
results indicate that fungal -1,3-glucan significantly influences
the ofloxacin tolerance of E. coli.
MATERIALS AND METHODS
Strains and media. C. albicans strains SC5314 (34), DAY185, and
CJN1201 (zap1/zap1) (35) and E. coli strain K-12 MG1655 (36) were
used in this study. Overnight cultures of C. albicans were grown in yeast
extract-peptone-dextrose (YPD; 1% yeast extract, 2% peptone, and 2%
dextrose) at 30°C. Overnight cultures of E. coli were grown in lysogeny
broth (LB) medium at 37°C. RPMI 1640 medium with L-glutamine and
without sodium bicarbonate was purchased from Sigma and buffered to
pH 7.0 with 3-N-morpholinepropanesulfonic acid (MOPS; final concen-
tration, 165 mM; Sigma, St. Louis, MO). Stock solutions of ofloxacin,
kanamycin, and laminarin from Laminaria digitata (all from Sigma, St.
Louis, MO) were prepared in Milli-Q water. Tetracycline hydrochloride
and amphotericin B were purchased from Sigma (St. Louis, MO), and
caspofungin (Cancidas) was purchased from Merck (Beeston, Notting-
ham, United Kingdom). Lyticase from Arthrobacter luteus, proteinase K
from Tritirachium album, N-acetylglucosaminidase from Canavalia ensi-
formis, and DNase I (all from Sigma, St. Louis, MO) were dissolved in
phosphate-buffered saline (PBS).
Growth of E. coli/C. albicans biofilms. Overnight cultures of C. albi-
cans andE. coliwere diluted inRPMI-MOPS to optical densities at 600 nm
(OD600) of 0.01 and 0.001, respectively. Equal volumes of these cell sus-
pensions were mixed, and 100 l of this mixed cell suspension was added
to the wells of a round-bottommicrotiter plate (TPP, Trasadingen, Swit-
zerland). Axenic biofilms were grown using identical inoculum densities
mixed with an equal volume of RPMI. After an adhesion phase of 4 h at
37°C under nonshaking conditions, nonadherent cells were removed by
rinsing with PBS. Fresh RPMI was added, and biofilms were grown for 24
h at 37°C. Afterwards, biofilms were rinsed with PBS and cells were resus-
pended in 100 l PBS after sonication (1 min, 45 kHz, USC300-T; VWR,
Radnor, PA, USA) and vigorous up-and-down pipetting. Dilution series
were made, and quantification of E. coli and C. albicans populations was
performed using selective plating, i.e., tryptic soy broth (TSB) plates con-
taining 25 g/ml amphotericin B and YPD plates containing 100 g/ml
tetracycline, respectively.
Visualization of biofilms. Biofilms were grown as described above,
using titanium disks (Ti-6Al-4V, grade 4, annealed, 1-mm sheet thickness
from GoodFellow; 15.5-mm diameter obtained by laser cutting with
LaserTek) as the substrate. Afterwards, samples were washed to remove
nonadherent cells by submerging samples carefully in PBS. Scanning elec-
tron microscopy (SEM) samples were prepared based on a previously
published protocol (21), with some adaptations. Samples were fixed with
2.5% glutaraldehyde (2.5% glutaraldehyde in cacodylate buffer [0.1 M,
pH 7.4]) for 30min and rinsed 3 times with PBS, followed by dehydration
in a series of ethanol washes (30, 50, 70, and 90% ethanol for 20 min).
Then, samples were soaked 3 times in 100% ethanol for 20 min each.
Following drying, samples were coated with Au-Pd using a sputtering
device (Edwards S150) in order to produce a thin conductive film on the
surface. A qualitative comparative analysis of the biofilms on various sam-
ples was done by SEM with an instrument (FEI XL30-FEG) operated at
standard high-vacuum settings and using a 10-mmworking distance and
5-keV accelerating voltage.
Antimicrobial biofilmassay.Biofilmswere grown for 24 h inRPMI as
described above. After rinsing with PBS, 2-fold dilution series of ofloxacin
(0.39 to 3.13 M), kanamycin (8 to 500 M), amphotericin B (0.04 to
1.25M), or caspofungin (0.07 to 2.5M)were prepared inRPMI, added
to the biofilms, and incubated for 24 h at 37°C. Afterwards, biofilm cells
were quantified as described above. Survival was calculated relative to the
control (vehicle treatment only;Milli-Q for ofloxacin and kanamycin and
0.5% DMSO [dimethyl sulfoxide] for amphotericin B and caspofungin).
Enzymatic degradation of the matrix. Biofilms were grown as de-
scribed above. Upon growth for 24 h at 37°C, the medium was replaced
with PBS containing lyticase, proteinase K, N-acetylglucosaminidase, or
DNase I (50 g/ml) for 2 h at 25°C (lyticase and N-acetylglucosamini-
dase) or 37°C (DNase I and proteinase K) (1, 37). PBS was used as a
control. Afterwards, biofilms were rinsed and RPMI containing 0.78 M
ofloxacin was added for 24 h at 37°C. Survival of biofilm cells was deter-
mined as described above.
Survival of C. albicans and E. coli cells upon treatment with en-
zymes. Overnight cultures of E. coli and C. albicans were diluted to an
OD600 of 0.01 in PBS containing 50g/ml lyticase, proteinaseK,N-acetyl-
glucosaminidase, or DNase and incubated for 2 h at 25°C (lyticase and
N-acetylglucosaminidase) or 37°C (DNase I and proteinase K). PBS was
used as a control. Survival of cells was monitored using CFU counts.
Antimicrobial biofilm assay in the presence of laminarin. An over-
night culture of E. coli was diluted in RPMI to an OD600 of 0.001. The
concentrations of laminarin were selected based on previous research in
the lab of D. Andes (38) and were 0.25 and 0.5 mg/ml. Stock solutions of
laminarin (1,000, 250 and 500 mg/ml) were made in Milli-Q water and
50 diluted in RPMI, resulting in the 20 stocks. Afterwards, 5 l of
these 20 stocks and 95l RPMI containing E. coli cells were added to the
wells of a round-bottommicrotiter plate, which was incubated for 4 h on
37°C. Next, nonadherent cells were removed by rinsing with PBS, and
fresh RPMI containing the appropriate amount of laminarinwas added to
the wells for 24 h at 37°C. Stock solutions of ofloxacin (1,000: 0, 0.39,
0.78, 1.56, and 3.13 mM) were made and 50 diluted in RPMI. Biofilms
were rinsed with PBS and RPMI with the appropriate concentrations of
ofloxacin, and laminarinwas added to the biofilms, whichwere allowed to
incubate for 24 h at 37°C. Afterwards, biofilms were washed and biofilm
mass was quantified using crystal violet or CFU.
Antimicrobial planktonic assay. Overnight cultures of C. albicans
and E. coli were diluted in RPMI-MOPS to OD600s of 0.01 and 0.001,
respectively. Equal volumes of these diluted cultures were mixed and
cocultured. As a control, the diluted E. coli culture was mixed with an
equal volume of RPMI. Cultures were grown for 24 h at 37°C, washedwith
PBS, and subdivided into Eppendorf tubes. After centrifugation, the su-
pernatant was removed. Stock solutions (200) of 2-fold concentration
series of ofloxacin were diluted in RPMI to their final concentration (0.09
to 0.075 M) and added to the Eppendorf tube. Suspended cultures were
transferred to glass tubes and incubated for 24 h at 37°C to mimic anti-
microbial biofilm assay conditions. Afterwards, cultures were quantified
as described above.
Statistical analysis. Results shown are means  standard deviations
from 3 independent biological experiments, each consisting of two tech-
nical replicates unless stated otherwise. Statistical analysis was performed
using two-way analysis of variance (ANOVA) and Bonferroni’s multiple-
comparison test unless stated otherwise.
RESULTS
C. albicans and E. coli form polymicrobial biofilms. The clini-
cally relevant RPMI medium was chosen as the growth medium
for E. coli/C. albicans biofilms because growth rates of C. albicans
and E. coli were comparable in this medium (results not shown).
E. coli/C. albicans biofilms were grown in RPMI using inoculation
OD600s of 0.01 and 0.001 for C. albicans and E. coli, respectively.
Visualization of E. coli/C. albicans biofilms, using scanning elec-
tron microscopy, showed the physical interaction between C. al-
bicans and the rod-shaped E. coli. Both C. albicans hyphal and
yeast cells are present in the E. coli/C. albicans biofilm (Fig. 1).
Subsequently, we assessed whether the inoculation density of one
of the species affected the density of the other species in an E.
coli/C. albicans biofilm. Increasing inoculation densities of E. coli
or C. albicans did not alter the number of CFU of C. albicans or E.
coli, respectively, in an E. coli/C. albicans biofilm compared to the
corresponding axenic biofilm, indicating that E. coli and C. albi-
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cans do not affect each other regarding their densities in the re-
spective biofilms (see Fig. S1 in the supplemental material).
E. coli is less susceptible to ofloxacin in an E. coli/C. albicans
biofilm. Next, we determined the antimicrobial sensitivity of E.
coli and C. albicans in an axenic biofilm and a polymicrobial bio-
film. First, E. coli/C. albicans and C. albicans biofilms were grown
in RPMI for 24 h, whereafter caspofungin or amphotericin B was
added for 24 h. Survival ofC. albicans upon treatment with caspo-
fungin or amphotericin B in an E. coli/C. albicans biofilm was not
significantly altered compared to survival in a C. albicans biofilm
(see Fig. S2 in the supplemental material). Second, E. coli/C. albi-
cans biofilms and E. coli biofilmswere grown for 24 h in RPMI and
subsequently treated with ofloxacin or kanamycin for 24 h. For all
indicated ofloxacin concentrations, survival of E. coli in an E. co-
li/C. albicans biofilm was significantly increased upon ofloxacin
treatment compared to survival of E. coli in an E. coli biofilm (Fig.
2), indicating that the presence of C. albicans reduces the efficacy
of ofloxacin to act against E. coli biofilm cells. In contrast, we
found that kanamycin tolerance ofE. colidid not differ between an
E. coli/C. albicans biofilm and an E. coli biofilm (results not
shown).
Increased ofloxacin tolerance of E. coli is primarily biofilm
specific. To test whether the observed increased ofloxacin toler-
ance of E. coli is biofilm specific, we assessed the viability of E. coli
upon ofloxacin treatment (0.09 to 0.75 M) under planktonic
conditions, in the presence or absence of C. albicans. Only for one
ofloxacin concentrationwas a significantly increased survival of E.
coli in the presence ofC. albicans observed compared to survival in
an axenic culture (Fig. 3), suggesting that biofilm-specific charac-
teristics, such as the extracellularmatrix, are importantmainly for
the observed ofloxacin tolerance of E. coli in an E. coli/C. albicans
biofilm.
Fungal -1,3-glucan increases ofloxacin tolerance of E. coli
in an E. coli/C. albicans biofilm. As the extracellular polymer
matrix is a key component of microbial biofilms, we examined
whether degradation of the extracellular matrix affects ofloxacin
tolerance of E. coli in an E. coli/C. albicans biofilm. The matrix of
FIG 1 Interaction ofC. albicans and E. coli in E. coli/C. albicans biofilms. E. coli andC. albicanswere grown for 24 h at 37°C using titanium disks as the substrate.
After dehydration, samples were visualized using SEM.
FIG 2 Increased ofloxacin tolerance of E. coli in an E. coli/C. albicans biofilm.
E. coli (gray bars) and E. coli/C. albicans (black bars) biofilms were treated with
different concentrations of ofloxacin (0.39 to 3.13 M). Afterwards, survival
of E. coli was quantified using selective plating. *, P 0.05; ***, P 0.001.
FIG 3 Increased ofloxacin tolerance of E. coli in the presence of C. albicans is
mainly biofilm specific. Survival of E. coli in planktonic conditions upon
ofloxacin treatment (0.09 to 0.75 M) was quantified in the absence (gray
bars) or presence (black bars) of C. albicans. *, P 0.05.
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C. albicans consists of proteins (55%), carbohydrates (15%), lipids
(15%), and nucleic acids (5%) (39). The exopolysaccharide moi-
ety contains -D-glucose, -D-glucose, -D-mannose, -L-rham-
nose, and N-acetylglucosamine subunits (40). We assessed the
involvement of these constituents in the observed ofloxacin toler-
ance by partially degrading the matrix of E. coli/C. albicans bio-
films using one of the following enzymes:-1,3-glucan-degrading
lyticase, N-acetylglucosaminidase, proteinase K, or DNase I (37).
Subsequently, biofilms were treated with 0.78 M ofloxacin, as
this concentration results in themost pronounced difference in E.
coli survival between E. coli and E. coli/C. albicans biofilms. We
found that degradation of the matrix by any of these enzymes
decreased the survival of E. coli in an E. coli/C. albicans biofilm up
to approximately 4-fold (Fig. 4). The most pronounced effect was
observed with lyticase, which hydrolyzes -1,3 glucan. Pretreat-
ment of E. coli/C. albicans biofilms with proteinase K or DNase I
resulted in a 2-fold-reduced survival of E. coli upon ofloxacin
treatment, while pretreatment with N-acetylglucosaminidase re-
sulted in aminor decrease inE. coli survival in anE. coli/C. albicans
biofilm. In contrast, none of the enzymes affected survival follow-
ing ofloxacin treatment of E. coli in an E. coli biofilm, indicating
that these enzymes primarily degrade the fungal matrix. Note that
the enzyme concentrations used did not affect survival of E. coli or
C. albicans cells itself (see Fig. S3 in the supplemental material).
To confirm our hypothesis that the observed ofloxacin toler-
ance of E. coli in an E. coli/C. albicans biofilm is mainly due to the
presence of -1,3-glucan, we examined the effect of exogenously
added laminarin (0 to 0.5mg/ml) on the viability of E. coli biofilm
cells in an E. coli biofilm upon ofloxacin treatment (0 to 3.13M).
Laminarin is a polysaccharide consisting of primarily poly--1,3-
glucan with some -1-6- interstrand linkages and branch points.
Addition of laminarin to E. coli biofilms results in significantly
increased E. coli survival upon ofloxacin treatment. For example,
treatment of an E. coli biofilm with 0.78 M ofloxacin resulted in
29.03%  2.33% survival, whereas addition of 0.5 mg/ml lami-
narin increased E. coli survival up to 43% 2.59% (Fig. 5) when
crystal violet was used as readout. In addition, results were con-
firmed using viable counts as a readout (see Fig. S4 in the supple-
mental material). In parallel, we also checked the ofloxacin toler-
ance of E. coli biofilm cells in an E. coli/C. albicans zap1/zap1
biofilm. A C. albicans zap1/zap1 strain produces 1.5- to 2-fold
more -1,3-glucan than does the wild type (35). Ofloxacin toler-
ance of E. coli in an E. coli/C. albicans zap1/zap1 biofilm was
significantly increased compared to ofloxacin tolerance of E. coli
in an E. coli/C. albicans wild-type biofilm (79%  3.58% and
57% 4.75%, respectively) (Fig. 6). Note that untreated E. coli/C.
albicans zap1/zap1 biofilms contain 1.7-fold more E. coli cells
than do E. coli/C. albicans wild-type biofilms (1.5 108 2.5
107 versus 8.8  107  1.3  107). All these data indicate that
-1,3-glucans produced by C. albicans can increase ofloxacin tol-
erance of E. coli.
DISCUSSION
In the past, research focused on monospecies biofilms. However,
it has become clear thatmost biofilms are polymicrobial in nature.
The interplay between microorganisms in these biofilms might
influence several characteristics of the polymicrobial biofilm, in-
FIG 4 The extracellular matrix contributes to the observed increased ofloxa-
cin tolerance of E. coli in an E. coli/C. albicans biofilm. E. coli/C. albicans and E.
coli biofilms were treated with 0.78 M ofloxacin with or without matrix-
degrading enzymes (50 g/ml). Afterwards, survival of E. coli was quantified
using selective plating. *, P 0.05; ***, P 0.001.
FIG 5 Exogenously added laminarin increases ofloxacin tolerance of E. coli in
anE. coli biofilm.AnE. coli biofilmwas treatedwith different concentrations of
ofloxacin in the presence or absence of different concentrations of laminarin (0
to 0.5 mg/ml). Biomass was quantified using crystal violet. **, P  0.01; ***,
P 0.001.
FIG 6 The presence of C. albicans zap1/zap1 increases ofloxacin tolerance
of E. coli to a greater extent than does the presence of C. albicans wild type. E.
coli/C. albicans biofilms consisting of E. coliwild type andC. albicanswild type
(black bars) or zap1/zap1 deletion mutant (gray bars) were treated with
0.78Mofloxacin. Afterwards, survival of E. coliwas quantified using selective
plating. Statistical analysis was performed using an unpaired t test. ***, P 
0.001.
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cluding drug tolerance (20–24). In this research, we compared the
tolerance levels of E. coli andC. albicans to different antimicrobial
agents inE. coli/C. albicans andmonospecies biofilms. To this end,
we first optimized a protocol to obtain E. coli/C. albicans biofilms.
SEM images of the E. coli/C. albicans biofilm showed the physical
interaction between the two species. In addition, we demonstrated
that the inoculation density of C. albicans does not affect the den-
sity of E. coli cells in a 24-h-old biofilm and vice versa. Note that
previously published research documented mutual antagonisms
between E. coli and C. albicans in an E. coli/C. albicans species
biofilms at defined time points (24, 41, 42). The different biofilm
setup (strains, medium, incubation time, etc.) between this study
and the previous studies (24, 41, 42) might account for these ob-
served differences.
Next, the effect of E. coli on C. albicans tolerance to amphoter-
icin B and caspofungin in an E. coli/C. albicans biofilm was deter-
mined. Tolerance ofC. albicans to amphotericin B or caspofungin
was not altered in an E. coli/C. albicans biofilm compared to an
axenic biofilm. In line with our results, it was previously demon-
strated that amphotericin B tolerance of C. albicans in a Staphylo-
coccus aureus/C. albicans biofilm is not altered compared to that in
a C. albicans biofilm (21).
In contrast to the results regarding tolerance ofC. albicans in E.
coli/C. albicans biofilms, we found that E. coli displays a signifi-
cantly increased ofloxacin tolerance in an E. coli/C. albicans bio-
film. Note that in general, oral doses of ofloxacin of 200 to 400mg
are given to patients every 12 h. Multiple-dose administration of
200-mg doses results in peak levels in serum of approximately 6
M ofloxacin in healthy male volunteers, indicating that the
ofloxacin concentrations used in this research are in line with
clinically relevant concentrations. As kanamycin tolerance was
not altered in an E. coli/C. albicans biofilm compared to an axenic
E. coli biofilm, this indicates that the observed increased tolerance
of E. coli in the presence of C. albicans is drug dependent, which is
in line with recently published research of Kart and colleagues,
who show that the effect of a species on the susceptibility of an-
other species depends on the disinfectant used (43). The increased
ofloxacin tolerance of E. coli in the presence of C. albicans is less
pronounced under planktonic conditions, suggesting that bio-
film-specific characteristics, such as the extracellular matrix,
might contribute significantly to this observed increased ofloxacin
tolerance. The possible contribution of matrix constituents was
tested using enzymes that specifically degrade matrix compo-
nents. Addition of these enzymes prior to ofloxacin treatment
decreased the ofloxacin tolerance of E. coli in an E. coli/C. albicans
biofilm. This effect was most pronounced using lyticase, which
hydrolyzes poly--(1-3)-glucose such as glucan, followed by pre-
treatment with proteinase K and DNase. This is remarkable, as
-1,3-glucan andDNA both constitute only a small portion of the
matrix (39).
Finally, we performed a detailed investigation of the effect of
-glucan on ofloxacin tolerance of E. coli in an E. coli/C. albicans
biofilm using a specific C. albicans zap1/zap1 deletion mutant
that produces significantly more -1,3-glucan than does the wild
type (35) and with exogenous addition of laminarin. The polysac-
charide laminarin consists primarily of poly--1,3-glucan with
some -1-6- interstrand linkages and branch points. First, we ob-
served that addition of exogenous laminarin to E. coli biofilms
increased the ofloxacin tolerance considerably. Second, our re-
sults showed that ofloxacin tolerance of E. coli is significantly in-
creased in an E. coli/C. albicans zap1/zap1 biofilm compared to
an E. coli/C. albicans wild-type biofilm. At present, we cannot
exclude that the disturbed hyphal morphogenesis of a C. albicans
zap1/zap1 biofilm, in which hyphae often end in yeast form
cells, contributes to the observed phenotype (35). However, com-
bined, these experiments indicate that -1,3-glucan seems to play
amajor role in the observed increased ofloxacin tolerance ofE. coli
in E. coli/C. albicans biofilms.
Also in other species, -1,3-glucan contributes to ofloxacin
tolerance. For example, a P. aeruginosa strain with a mutation in
ndvB, required for the formation of highly glycerol-phosphory-
lated -1,3-glucans (44), displays decreased ofloxacin tolerance
when grown in a biofilm compared to the wild type (45).
As -1,3-glucan has been linked to impeded drug penetration
in C. albicans biofilms (39, 46–48), a plausible explanation for the
observed phenotypemight be that-1,3-glucan sequesters ofloxa-
cin in an E. coli/C. albicans biofilm. Results of Jefferson and col-
leagues indicate that the increased vancomycin tolerance of S. au-
reus in a biofilm compared to its tolerance in planktonic cells
could be due to a decreased penetration rate of vancomycin into
the biofilm (49). Similarly, the presence of fungal -1,3-glucan in
an E. coli/C. albicans biofilm might account for a decreased pene-
tration rate of ofloxacin into the biofilm, resulting in an initial
exposure to a low ofloxacin concentration, which might give E.
coli the time to initiate a defensive response.
Previous research showed that C. albicans also increases toler-
ance of S. aureus and Staphylococcus epidermidis to vancomycin
(21, 22).Whereas the presence ofC. albicansmay be considered to
be of minor importance in polymicrobial biofilm-associated in-
fections, the observed increased tolerance of different Gram-pos-
itive and Gram-negative bacteria to different antibiotics, in the
presence of C. albicans, indicates that C. albicans could have im-
portant clinical consequences in the treatment of these infections.
In conclusion, we show for the first time that -1,3-glucan
produced by the yeast C. albicans contributes to the observed in-
creased ofloxacin tolerance of E. coli when grown in an E. coli/C.
albicans biofilm. The clinical significance of these in vitro data will
have to be determined using in vivo animal models.
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